Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Extending residence time and stability of peptides by protected graft copolymer (PGC) excipient: GLP-1 example.

Castillo GM, Reichstetter S, Bolotin EM.

Pharm Res. 2012 Jan;29(1):306-18. doi: 10.1007/s11095-011-0542-2. Epub 2011 Aug 4.

2.

GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1.

Li Y, Zheng X, Tang L, Xu W, Gong M.

Peptides. 2011 Jun;32(6):1303-12. doi: 10.1016/j.peptides.2011.04.001. Epub 2011 Apr 14.

PMID:
21515323
3.
4.
5.

Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.

Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, Junien JL, Aubert ML.

Diabetes. 2002 May;51(5):1461-9.

6.

Synergistic effect of the human GLP-1 analogue liraglutide and a dual PPARalpha/gamma agonist on glycaemic control in Zucker diabetic fatty rats.

Brand CL, Galsgaard ED, Tornehave D, Rømer J, Gotfredsen CF, Wassermann K, Knudsen LB, Vølund A, Sturis J.

Diabetes Obes Metab. 2009 Aug;11(8):795-803. doi: 10.1111/j.1463-1326.2009.01049.x. Epub 2009 Jun 10.

PMID:
19519868
8.

Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.

Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HH.

Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1407-14. doi: 10.1161/ATVBAHA.110.206425. Epub 2010 May 6.

9.

A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo.

Li Y, Xu W, Tang L, Gong M, Zhang J.

Peptides. 2011 Jul;32(7):1408-14. doi: 10.1016/j.peptides.2011.05.026. Epub 2011 Jun 12.

PMID:
21664938
10.

Taspoglutide, a novel human once-weekly GLP-1 analogue, protects pancreatic β-cells in vitro and preserves islet structure and function in the Zucker diabetic fatty rat in vivo.

Uhles S, Wang H, Bénardeau A, Prummer M, Brecheisen M, Sewing S, Tobalina L, Bosco D, Wollheim CB, Migliorini C, Sebokova E.

Diabetes Obes Metab. 2011 Apr;13(4):326-36. doi: 10.1111/j.1463-1326.2010.01352.x.

PMID:
21205124
11.

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.

Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, Shao YM, Park TS.

J Pharmacol Exp Ther. 2012 Feb;340(2):248-55. doi: 10.1124/jpet.111.186866. Epub 2011 Oct 24.

12.

Disulfide bond prolongs the half-life of therapeutic peptide-GLP-1.

Li Y, Li X, Zheng X, Tang L, Xu W, Gong M.

Peptides. 2011 Jul;32(7):1400-7. doi: 10.1016/j.peptides.2011.05.003. Epub 2011 May 11.

PMID:
21600946
13.

Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1.

Lee SH, Lee S, Youn YS, Na DH, Chae SY, Byun Y, Lee KC.

Bioconjug Chem. 2005 Mar-Apr;16(2):377-82.

PMID:
15769092
14.

Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.

Chae SY, Jin CH, Shin HJ, Youn YS, Lee S, Lee KC.

Bioconjug Chem. 2008 Jan;19(1):334-41. Epub 2007 Dec 14.

PMID:
18078308
16.

Stability and bioactivity studies on dipeptidyl peptidase IV resistant glucogan-like peptide-1 analogues.

Chen W, Zhou Y, Zhang H, Qian H, Huang W, Yang B, Han J, Zhou J, Chi Y, Ni S.

Protein Pept Lett. 2012 Feb;19(2):203-11.

PMID:
21838700
17.

The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent.

Furman BL.

Toxicon. 2012 Mar 15;59(4):464-71. doi: 10.1016/j.toxicon.2010.12.016. Epub 2010 Dec 29.

PMID:
21194543
18.

Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.

Holst JJ.

Expert Opin Emerg Drugs. 2004 May;9(1):155-66. Review.

PMID:
15155141
19.

Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats.

Lee Y, Kwon MK, Kang ES, Park YM, Choi SH, Ahn CW, Kim KS, Park CW, Cha BS, Kim SW, Sung JK, Lee EJ, Lee HC.

J Gene Med. 2008 Mar;10(3):260-8.

PMID:
18085721
20.

Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration.

Hargrove DM, Nardone NA, Persson LM, Parker JC, Stevenson RW.

Metabolism. 1995 Sep;44(9):1231-7.

PMID:
7666800
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk